Shepard Goldberg

Shepard Goldberg

Objective

Currently, I am looking to continue my career in a senior executive role where I can lead business transformation, sales & marketing, process redesign, organizational growth, and other operating functions with a competitively driven organization which is ready to take the next step in its development.

Summary

SENIOR OPERATING and MANAGEMENT EXECUTIVE President / CEO / Chief Operating Officer leading high growth organizational development Comprehensive operating management background with innovative pharmaceutical company, privately held manufacturing venture, and IT systems integrator. Visionary leadership evidenced through creating synergies and building high-performance teams in change-intensive environments. Organizational driver and consummate business leader with strong track record in start-up, turnaround, and high growth organizations. Versatile internal CEO, consensus builder, and noted multi-tasker with solid history of solving myriad business problems through calm understanding, enlightened perspective, and decisive execution.

Work History

Work History
Jan 2010 - Present

CEO, Board Director

Cordex Pharma, Inc.

Cordex Pharma, Inc. (Cordex) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders.

Cordex is developing a portfolio of therapeutic and diagnostic products, two of which are in advanced stages of clinical studies. Cordex is now preparing for a pivotal Phase 3 clinical trial with ATPace as an anti-arrhythmic drug for the treatment of paroxysmal supraventricular tachycardia and a proof-of-concept Phase 2 clinical trial with CDP-1050 for the treatment of heart failure. In addition, Cordex has a preclinical drug discovery program aimed at a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease and chronic cough.

Jan 2008 - Present

Principal

SMG Consulting

Provide management consulting for small and medium size businesses that require a trusted advisor and are in need of marketing & business development, growth & profit strategies, turnaround management services, and financial management.My clients get practical solutions which impact organizational growth, create strategic alliances and partnerships, improve customer retention, heighten brand loyalty and increase top and bottom-line results.

2007 - Present

Chairman

Forticell Bioscience, Inc Inc.

Forticell is a company focused on advancing regenerative medicine and stem cell therapy through the development and commercialization of innovative products by combining advanced cell technology and advanced biomaterials. Forticell’s lead product is OrCel® (Bilayered Cellular Matrix). Forticell’s current focus is the application of OrCel® to heal chronic and acute wounds. OrCel® is composed of a collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue repair

Oct 2007 - Jan 2010

Board Director, Audit Chair

Cordex Pharma, Inc.

Cordex Pharma, Inc. (Cordex) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders.

Cordex is developing a portfolio of therapeutic and diagnostic products, two of which are in advanced stages of clinical studies. Cordex is now preparing for a pivotal Phase 3 clinical trial with ATPace as an anti-arrhythmic drug for the treatment of paroxysmal supraventricular tachycardia and a proof-of-concept Phase 2 clinical trial with CDP-1050 for the treatment of heart failure. In addition, Cordex has a preclinical drug discovery program aimed at a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease and chronic cough.

1998 - Dec 2007

Senior Vice President

Emisphere Technologies, Inc.

Biopharmaceutical company charting new frontiers in drug delivery.Core business strategy is to develop oral forms of injectable drugs by applying proprietary eligen® technology to drugs. Has built strategic alliances with world-leading pharmaceutical companies

Senior Vice President, Operations; Office of the President2001 to present In charge of Finance & Accounting; Information Technologies; Vivarium Operations; Corporate Design and Creative Services; Facilities; Safety; Purchasing; Project Management; Regulatory Affairs; Quality; Manufacturing; Chemistry; Drug Development.Serve on executive leadership teams – Chair Contract and Disclosure Controls & Procedures Committees; member, Promotion Review and Rewards/Recognition Committees; member, Financial Review Team for 401k Plan and Benefits.Designated Institutional Officer - oversee animal research and Institutional Animal Care and Use Committee (IACUC).Staff: 50+; report to Chief Executive Officer.

  • CEO for acquired FarmTech subsidiary, overseeing day-to-day operations of Farmington, CT site - revamped infrastructure through change initiatives regarding human capital, processes, and operations, i.e., staffing; purchasing; rehabilitation of laboratory operations; budgeting; systems, and processes, updating SOPs, and computer systems.Signatory on regulatory permits, interface with parent.
  • Created synergies through the development of close working relationship between Emisphere and FarmTech science staff allowing data produced to be more meaningful which fostered faster development of technology.Established capabilities for handling GLP stability, Non-Human Primate (NHP), rabbit, and rodent studies, Radio Chemistry lab, and bioanalytical and chromatographic assays.Laid groundwork for GLP Toxicology work.
  • After Emisphere’s focus changed, sold FarmTech facility recouping original cost and capital improvements invested - identified and supervised real estate broker; worked with local government officials and company attorneys on zoning and environmental concerns; negotiated final price directly with buyer; managed outside attorneys to finalize all paperwork and close transaction.
  • Instituted massive cost control programs including upgrade of financial systems to Oracle Financials and establishment of peer review process for all large expenditures through the Contract Committee.
  • Collaborated with CFO to form and manage Sarbanes-Oxley (Sarbox) implementation team; sourced and managed outside Sarbox consultant; led Information Technology compliance effort, identified IT controls; worked with auditors through testing process; served as Chair of Disclosure Controls and Procedures Committee
  • Passed Sarbox compliance audit with no significant observations, a critical requirement to operate as a public company and continue to raise money in the public markets.Significant cost savings achieved by handling bulk of IT compliance internally.

Vice President, Operations1998 to 2001

Managed Finance & Accounting; Information Technologies; Corporate Design and Creative Services; Facilities; Safety; Purchasing; Regulatory Affairs.Served on executive leadership teams – Chair Contract; member, Promotion Review and Rewards/Recognition Committees; member, Financial Review Team for 401k Plan and Benefits.Staff: 20+; reported to Chief Executive Officer.

  • Rescued stalled $35MM, three-year international, multi-center phase III trial - 2,200 patients at 125+ sites in 10 countries.Led all operations - established clear responsibilities with internal and external teams; identified bottlenecks and instituted changes to streamline workflow and simplify execution of trial while maintaining quality and integrity of data; contracted with additional Contract Research Organizations to expand countries and sites resulting in increased enrollment rates; negotiated contracts and budgets with outside vendors; point of contact with outside scientific advisors allowing them to give valuable support and input to the progress of the trial.
  • Led $30MM construction project for 120,000 square feet of mixed laboratory and office space - formed internal team to identify user requirements; negotiated with landlord to identify and lease required space; contracted with vendors (architect, engineer, general contractor, etc.); oversaw design and construction offacility; formed and managed validation team, allowing space to be used for FDA approved GMP manufacturing.
1977 - 1998

President

Hydrovalve Co., Inc.

Privately held manufacturing/distribution business (60+ employees) with national and Canadian catalog sales serviced through 3 warehouse locations

Grew seasonal heating business 300% to complementary heating/pool products company generating $16+MM revenues and year-round positive cash flow.In 1997 sold heating component to upstream manufacturer/distributor; 1998, sold pool products business to large competitor.

1982 - 1990

Vice President

Computer Network, Inc.

Co-founded, co-managed two-location computer retailer specializing in desktop publishing and networking, selling IBM PC and Apple Macintosh solutions.Concurrent with Hydrovalve.

Grew annual sales from $0 to $5 million in less than six years.Planned and oversaw retail store design and construction in regional mall.Trained personnel in computer software and hardware, sales and customer service.Coordinated local advertising campaign including radio and newspaper ads. Managed store display and signage. Negotiated sale of company to national retail computer chain, 1990.

Education

Education

MBA

http://www.adelphi.edu

Adelphi University School of Business, accredited by AACSB International, combines a cutting-edge curriculum with personal attention from expert faculty to create leaders who have the knowledge, integrity, and originality to drive enterprise in the 21st century. Small classes, state-of-the-art instruction, a richly diverse student body, and hands-on experience enable students to excel in all aspects of management

BS

Polytechnic Institute of NYU

The Department of Electrical & Computer Engineering at Polytechnic Institute of NYU has a long tradition of excellence in teaching and research, starting with the inception of the Electrical Engineering program at "Brooklyn Poly" in 1885. The department rose to prominence in the mid-twentieth century for work in microwaves, communications, electrical machinery, and automatic control.  Current research and degree programs focus on:

  • Telecommunications (including Wireless and High-Speed Networks)
  • Digital Signal Processing (including still and video image processing)
  • Computer Engineering
  • Control and Robotics
  • Electrical Power Systems
  • Electromagnetics & Microwaves
  • Electrophysics of materials (especially plasmas)

References

References

Richard Connor

Michael Goldberg

Barbara Mohl

Stewart Siskind